BLU9931 Chemical Properties

Density 

1.361±0.06 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

≥50.9 mg/mL in DMSO; insoluble in H2O; ≥2.53 mg/mL in EtOH with gentle warming and ultrasonic

form 

Powder

pka

13.15±0.70(Predicted)

color 

Off-white to light yellow

BLU9931 Usage And Synthesis

Uses

BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 3 nM and a Kd of 6 nM. BLU9931 has significant antitumor activity[1].

Definition

BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 3 nM and a Kd of 6 nM. BLU9931 has significant antitumor activity. BLU9931 makes a covalent bond with Cys552 within the ATP-binding pocket of FGFR4, which is not present in FGFR1-3. BLU9931 inhibited gastric cancer cell growth in a transplanted mouse model[1].

Synthesis

The general procedure for the synthesis of N-[2-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]-3-methylphenyl]-2-acrylamide from the compound (CAS: 1538605-10-5) and acryloyl chloride was performed as follows: the N'-[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]- 6-methylbenzene-1,2-diamine (5.16 g, 11.33 mmol) was dissolved in dichloromethane (DCM, 100 mL) and cooled to 0 °C. Subsequently, N,N-diisopropylethylamine (DIEA, 1.781 mL, 10.20 mmol) and acryloyl chloride (1.013 mL, 12.47 mmol) were sequentially added at 0 °C and the reaction mixture was stirred for 2 h at this temperature. After completion of the reaction, the mixture was directly sampled onto a silica gel column and purified by fast column chromatography using 0-100% ethyl acetate (EtOAc)/hexane gradient elution. Finally, the target product N-[2-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]-3-methylphenyl]-2-propenamide was obtained as an off-white solid (3.5 g, 61% yield). The mass spectrum (electrospray positive ion mode, ES+) showed the molecular ion peak m/z 509 [M+H]+, which is consistent with the calculated value of the molecular formula C26H22Cl2N4O3.1H NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H), 9.23 (s, 1H), 8.68 (s, 1H), 7.82-7.65 (m, 2H) , 7.51 (s, 2H), 7.21 (m, 1H), 7.12 (d, J = 6.8 Hz, 1H), 7.01 (s, 1H), 6.49 (dd, J = 17.0, 10.2 Hz, 1H), 6.28-6.15 (m, 1H), 5.68 (dd, J = 10.2, 2.0 Hz, 1H), 3.97 (s, 6H) , 2.19 (s, 3H).

in vivo

IC 50

FGFR1: 591 nM (IC₅₀); FGFR2: 493 nM (IC₅₀); FGFR3: 150 nM (IC₅₀); FGFR4: 3 nM (IC₅₀)

References

[1] Norihiko Sasaki. “FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer.” Cancers (2020).

BLU9931(1538604-68-0)Related Product Information

• 1 NM-PP1
• ZLN005
• Esomeprazole magnesium
• Tariquidar
• Palbociclib
• IXABEPILONE
• PF-04929113
• 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide
• L-4-THIAZOLYLALANINE
• Ilomastat
• AZD-1208
• Crenolanib
• Doxorubicin hydrochloride
• AZD6738
• 2-(2-Chlorophenyl)-4-(3-(diMethylaMino)phenyl)-5-Methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione
• Enasidenib
• RVX-208
• Pralsetinib